Health researchers work with startup on colon cancer vaccine

January 17, 2017 by Jessica Mcbride
Kepeng Wang, assistant professor of immunology, right, works with research associate Kasandra Rodriguez in the lab at CaroGen Corp. in the technology incubator at Farmington. Credit: Peter Morenus/UConn Photo

The University of Connecticut and emerging immunotherapy company CaroGen Corp. have begun a collaboration to develop a vaccine for treatment of patients with colon cancer.

CaroGen's proprietary technology platform will be applied to a specific target studied by UConn Health researchers Kepeng Wang, assistant professor of immunology, and Anthony T. Vella, professor and Boehringer Ingelheim Chair in Immunology.

CaroGen Corp.'s platform is a transformative virus-like vesicle (VLV) technology developed at Yale University School of Medicine and exclusively licensed by CaroGen for the development and commercialization of immunotherapies worldwide.

Colon cancer is the second leading cause of cancer-related deaths in the United States. It is expected to cause over 49,000 deaths during 2016, and the risk to individuals increases with age. Wang's target, Interleukin-17 (IL-17), a pleiotropic pro inflammatory cytokine, can promote cancer-elicited inflammation and prevent cancer cells from immune surveillance.

"While the death rate from has been dropping for several decades thanks to screening and improved treatment, our goal is to reach close to a 100 percent survival rate," said CaroGen's President and CEO, Bijan Almassian. "By combining our platform with Dr. Wang's very promising target, we hope that a new powerful immunotherapy will be developed to provide patients with that assurance."

The company will have the right to exclusively license intellectual property developed by UConn through this collaboration, for human and animal health use.

The company is one of 21 biotech startups now housed at the Technology Incubator Program (TIP) on the UConn Health campus in Farmington, which helps develop new biotechnology concepts into businesses. CaroGen is leveraging the resources of the program to develop a portfolio of immunotherapies, with a lead program in chronic hepatitis B viral infection in collaboration with researchers from Yale University School of Medicine and Albany Medical College.

It is also working on the development of VLV immunotherapies against C. difficile bacterial infection in collaboration with Kamal Khanna, assistant professor of immunology at UConn Health, and a vaccine against the Zika virus with Paulo Verardi, associate professor of pathology at UConn Storrs.

"CaroGen is proving to be both a scientific and entrepreneurial leader in Connecticut," said Dr. Jeff Seemann, UConn's vice president for research. "Dr. Almassian has led multiple efforts to apply the CaroGen technology in collaborations with UConn researchers where critical and urgent health care needs exist. We are very excited about this latest endeavor, which we believe will yield significant therapeutic and commercial opportunities through the combined expertise of UConn Health's Department of Immunology and CaroGen."

Explore further: Advanced lung cancer knocked out in clinical trial

Related Stories

Advanced lung cancer knocked out in clinical trial

December 14, 2016
A leading-edge immunotherapy clinical trial at UConn Health's Carole and Ray Neag Comprehensive Cancer Center has packed a one-two punch, successfully controlling a patient's advanced lung cancer using the combined power ...

Researchers develop personalized ovarian cancer vaccines

October 7, 2014
Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer.

Auditors: National Science Foundation suspends UConn grants

May 1, 2015
The National Science Foundation has frozen more than $2 million in grants to the University of Connecticut after a foundation investigation found two professors used grant money to buy products from their own company, Connecticut ...

Walnuts may improve your colon health

June 2, 2016
Eating walnuts may change gut bacteria in a way that suppresses colon cancer, researchers led by UConn Health report in the journal Cancer Prevention Research.

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.